Mylan and Upjohn’s merger plans face New Zealand regulatory review with pricing, quality focus
Plans by US-based pharmaceutical company Mylan to combine with Pfizer’s off-patent drug business Upjohn are under scrutiny in New Zealand after the country’s competition regulator announced today it had started a...To view the full article, register now.
Already a subscriber? Click here to view full article